内容紹介
A Case of an Ulcer of the Sigmoid Colon during Chemotherapy with FOLFOX4 and Bevacizumab for Recurrence of Rectal Carcinoma
Summary
The patient was a 73-year-old female. After curative resection for rectal cancer with uterus invasion, UFT/Leucovorin was administered orally for 16 months. Three years and six months after the initial surgery, en bloc cystourethrectomy was performed to control the bleeding caused by a local recurrence invading the bladder and ureter. Although postoperative FOLFOX4/bevacizumab therapy was started, bevacizumab was discontinued after 4 courses of treatment because an ulcer was confirmed at the sigmoid colon with stoma. The ulcer was relieved by conservative medical treatment. In this case, we attempted to make a quick response because the site of the ulcer could be easily observed. During chemotherapy. Therefore, it is necessary to carefully observe the patient's conditions.
要旨
症例は73歳,女性。子宮浸潤を伴う直腸癌に対して手術を施行,根治手術となりUFT/Leucovorin内服療法を16か月行った。初回手術3年6か月後に膀胱,尿管浸潤を伴う局所再発を来し,出血コントロールのため膀胱尿道全摘術を行った。術後FOLFOX4/bevacizumabによる化学療法を導入したが,4コース終了後にストーマ腸管に潰瘍を認めたためbevacizumabを中止し,保存的加療にて軽快した。本例のように潰瘍発生部位が容易に観察できる部位であったため迅速な対応が可能であったが,化学療法中は患者の症状を注意深く観察することが必要である。
目次
Summary
The patient was a 73-year-old female. After curative resection for rectal cancer with uterus invasion, UFT/Leucovorin was administered orally for 16 months. Three years and six months after the initial surgery, en bloc cystourethrectomy was performed to control the bleeding caused by a local recurrence invading the bladder and ureter. Although postoperative FOLFOX4/bevacizumab therapy was started, bevacizumab was discontinued after 4 courses of treatment because an ulcer was confirmed at the sigmoid colon with stoma. The ulcer was relieved by conservative medical treatment. In this case, we attempted to make a quick response because the site of the ulcer could be easily observed. During chemotherapy. Therefore, it is necessary to carefully observe the patient's conditions.
要旨
症例は73歳,女性。子宮浸潤を伴う直腸癌に対して手術を施行,根治手術となりUFT/Leucovorin内服療法を16か月行った。初回手術3年6か月後に膀胱,尿管浸潤を伴う局所再発を来し,出血コントロールのため膀胱尿道全摘術を行った。術後FOLFOX4/bevacizumabによる化学療法を導入したが,4コース終了後にストーマ腸管に潰瘍を認めたためbevacizumabを中止し,保存的加療にて軽快した。本例のように潰瘍発生部位が容易に観察できる部位であったため迅速な対応が可能であったが,化学療法中は患者の症状を注意深く観察することが必要である。